Crescent Biopharma, Inc.
CBIO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001253689
In the last 90 days, Crescent Biopharma, Inc. insiders filed 1 open-market purchase and 7 sales; 82 institutions reported holding it in 13F filings for Q2 2026, worth $532.6M in total; no superinvestor holds it.
13F holders, Q3 2025
Institutional positions in Crescent Biopharma, Inc. as of Sep 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 41
- +11 vs. Q2 2025
- Shares held
- 11.3M
- +567.1K (+5.3%) vs. Q2 2025
- Total value
- $134.6M
- −$39.0M (−22.4%) vs. Q2 2025
- New holders
- 15
- 7 more added
- Sold out
- 4
- 8 more reduced
Compare with Q2 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CBIO on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 82 | $532.6M |
| Q1 2026 | 63 | $476.6M |
| Q4 2025 | 58 | $285.9M |
| Q3 2025 | 41 | $134.6M |
| Q2 2025 | 30 | $173.5M |
| Q1 2025 | 35 | $6.46M |
| Q4 2024 | 41 | $7.56M |
| Q3 2024 | 36 | $3.00M |
| Q2 2024 | 35 | $7.20M |
| Q1 2024 | 69 | $110.5M |
| Q4 2023 | 58 | $82.8M |
| Q3 2023 | 49 | $52.1M |
| Q2 2023 | 55 | $61.9M |
| Q1 2023 | 54 | $46.6M |
| Q4 2022 | 48 | $83.3M |
| Q3 2022 | 35 | $14.3M |
| Q2 2022 | 37 | $15.8M |
| Q1 2022 | 44 | $31.2M |
| Q4 2021 | 47 | $42.7M |
| Q3 2021 | 48 | $64.9M |
| Q2 2021 | 58 | $72.5M |
| Q1 2021 | 78 | $110.4M |
Institutions, Q3 2025
Shares, value and share of portfolio for each institution holding Crescent Biopharma, Inc.; share changes are against Q2 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Royal Bank of Canada | 20 | $0 | 0.00% | 00.0% | Unchanged |
| BNP Paribas Arbitrage, SA | 4 | $48 | 0.00% | 00.0% | Unchanged |
| JPMorgan Chase & Co | 17 | $202 | 0.00% | +17 | New |
| Advisor Group Holdings, Inc. | 26 | $374 | 0.00% | +26 | New |
| SBI Securities Co., Ltd. | 68 | $809 | 0.00% | 00.0% | Unchanged |
| Group One Trading, L.P. | 82 | $975 | 0.00% | −80−49.4% | Reduced |
| Morgan Stanley | 145 | $1.72K | 0.00% | −15,249−99.1% | Reduced |
| Tower Research Capital LLC (TRC) | 200 | $2.38K | 0.00% | +200 | New |
| Citigroup Inc | 798 | $9.49K | 0.00% | +798 | New |
| Bank of America Corp | 3,863 | $45.9K | 0.00% | −5,368−58.2% | Reduced |
| UBS Group AG | 12,661 | $150.5K | 0.00% | +12,438+5,577.6% | Added |
| Northern Trust Corp | 16,816 | $199.9K | 0.00% | +16,816 | New |
| Wellington Management Group LLP | 17,698 | $210.4K | 0.00% | −162,188−90.2% | Reduced |
| Affinity Asset Advisors, LLC | 17,998 | $214.0K | 0.02% | −262,033−93.6% | Reduced |
| State Street Corp | 18,617 | $221.4K | 0.00% | +18,617 | New |
| Manufacturers Life Insurance Company, The | 24,923 | $296.3K | 0.00% | +24,923 | New |
| Citadel Advisors LLC | 25,593 | $304.3K | 0.00% | +25,593 | New |
| Renaissance Technologies LLC | 26,900 | $319.8K | 0.00% | +26,900 | New |
| Two Sigma Investments, LP | 28,318 | $336.7K | 0.00% | +28,318 | New |
| Goldman Sachs Group Inc | 36,975 | $439.6K | 0.00% | +36,975 | New |
| Marshall Wace, LLP | 43,694 | $519.5K | 0.00% | +43,694 | New |
| Geode Capital Management, LLC | 69,134 | $822.0K | 0.00% | +69,134 | New |
| Blackstone Group Inc. | 75,614 | $899.0K | 0.00% | 00.0% | Unchanged |
| Jefferies Financial Group Inc. | 102,714 | $1.22M | 0.01% | +75,618+279.1% | Added |
| BlackRock, Inc. | 109,115 | $1.30M | 0.00% | +103,064+1,703.3% | Added |
| Soleus Capital Management, L.P. | 200,000 | $2.38M | 0.13% | −200,000−50.0% | Reduced |
| Adage Capital Partners GP, L.L.C. | 200,005 | $2.38M | 0.00% | +99,093+98.2% | Added |
| Frazier Life Sciences Management, L.P. | 272,951 | $3.25M | 0.10% | −180,734−39.8% | Reduced |
| Driehaus Capital Management LLC | 302,457 | $3.60M | 0.03% | 00.0% | Unchanged |
| Price T Rowe Associates Inc | 383,595 | $4.56M | 0.00% | +383,595 | New |
| Commodore Capital LP | 450,829 | $5.36M | 0.26% | −2,857−0.6% | Reduced |
| Deep Track Capital, LP | 453,686 | $5.39M | 0.15% | 00.0% | Unchanged |
| Boxer Capital Management, LLC | 453,686 | $5.39M | 1.72% | 00.0% | Unchanged |
| Perceptive Advisors LLC | 453,686 | $5.39M | 0.16% | 00.0% | Unchanged |
| Logos Global Management LP | 600,000 | $7.13M | 0.70% | +46,314+8.4% | Added |
| Vanguard Group Inc | 657,900 | $7.82M | 0.00% | +657,900 | New |
| Tang Capital Management LLC | 679,824 | $8.08M | 0.31% | +629,672+1,255.5% | Added |
| BVF Inc | 1,387,863 | $16.5M | 0.67% | 00.0% | Unchanged |
| VR Adviser, LLC | 1,387,864 | $16.5M | 0.93% | 00.0% | Unchanged |
| Fairmount Funds Management LLC | 1,387,866 | $16.5M | 1.48% | 00.0% | Unchanged |
| FMR LLC | 1,414,680 | $16.8M | 0.00% | +4900.0% | Added |
| Paradigm Biocapital Advisors LP | 0 | $0 | 0.00% | −642,721−100.0% | Sold out |
| Braidwell LP | 0 | $0 | 0.00% | −261,504−100.0% | Sold out |
| Barclays PLC | 0 | $0 | 0.00% | −286−100.0% | Sold out |
| Raymond James Financial Inc | 0 | $0 | 0.00% | −50−100.0% | Sold out |